1300 GMT - Roche's $50 billion U.S. investment signals that president Trump's pressure tactics amid tariffs prospects are proving effective, AlphaValue analysts say in a note. The Swiss pharma giant's five-year $50 billion pledge in U.S. manufacturing and R&D joins a growing trend of companies increasing investment in the country, they say. Roche shares fall 2% to 250.60 Swiss Francs. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 22, 2025 09:03 ET (13:03 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.